PetVivo Targets $40B Veterinary Market with Regenerative Joint Therapy and AI Vet Platform

For veterinarians, pet owners, and animal-health investors, this New to The Street presentation highlights PetVivo Holdings and its regenerative medicine technologies designed to treat osteoarthritis and joint damage in companion animals. The company’s flagship product Spryng with OsteoCushion Technology uses naturally derived biomaterials that mimic cartilage and integrate into the joint to restore function and reduce inflammation, while Precise PRP provides an off-the-shelf platelet-rich plasma therapy that saves veterinarians time and improves treatment consistency.

PetVivo is also expanding through a nationwide partnership covering more than 7,000 veterinary clinics and is preparing to launch PetVivo AI, a diagnostic and practice-management platform designed to help veterinarians analyze patient data, improve treatment recommendations, and reduce client acquisition costs. With strong intellectual property, scalable manufacturing, and growing demand for advanced pet healthcare, the company is positioning itself at the intersection of regenerative medicine, veterinary technology, and AI-driven diagnostics.

#PetVivo #VeterinaryMedicine #AnimalHealth #PetHealthcare #RegenerativeMedicine #Osteoarthritis #VeterinaryInnovation #PetTech #AIinVeterinary #JointHealth #Biotech #VeterinaryClinics #AnimalWellness #NewToTheStreet